CD19 and cancer: As we gain experience with CARs other than CD19-directed therapies, we will achieve increasing clarity whether different targets are associated with different toxicity profiles, or whether ICANS is truly a single syndrome that represents a final common pathway of neuroinflammation related to immune-effector cell engaging cancer therapies.